Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder
Status:
Recruiting
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to demonstrate improvement of the T regulatory cells (Treg)
response, under add on low-dose Interleukin 2 (ld-IL2) in patients with bipolar disorders
experiencing a depressive relapse